IL10 and relapsing-remitting multiple sclerosis: In a randomised controlled trial involving 14 patients with relapsing-remitting MS, PBM therapy to the sublingual region or over the radial artery using 808 nm wavelength and output power of 100 mW for 360 s, twice weekly for 24 sessions, led to significant increases in levels of anti-inflammatory cytokine, IL-10, in peripheral blood from both treatment groups but the levels of nitrites, which are metabolites of nitric oxide and are released by microglia and contribute to oxidative stress and demyelination, were not modulated in either treatment group (35).